NFKB1 and neoplasm: This resistance is caused by a decrease of cleaved caspases upon treatment, activation of the canonical NF-κB pathway, and dysregulation of genes acting as direct interaction hubs, including down-regulated NF-κB target genes with known anti-tumor activity.